Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs. Sisa I, Noblecilla E, Orozco F. Lancet 2021 Feb 19. pii: S0140-6736(21)00357.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sisa I, Noblecilla E, Orozco F. Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs. Lancet 2021 Feb 19. pii: S0140-6736(21)00357.
PMID: 33617776